Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 355-364, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-64170
ABSTRACT
PURPOSE:
HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in colorectal cancer (CRC) cell lines. MATERIALS ANDMETHODS:
The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between 2 drugs was evaluated by the combination index.RESULTS:
The addition of HM781-36B induced potent growth inhibition in both DiFi cells with EGFR overexpression and SNU-175 cells (IC50 = 0.003 and 0.005 microM, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells.CONCLUSION:
These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, singly or in combination with chemotherapeutic agents. The role of BMX expression as a marker of response to HM781-36B should be further explored.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosfotransferasas
/
Proteínas Tirosina Quinasas
/
Neoplasias Colorrectales
/
Ciclo Celular
/
Línea Celular
/
Supervivencia Celular
/
Apoptosis
/
Neoplasias del Colon
/
Citoplasma
/
Receptores ErbB
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS